•  

International Projects

TIAP and Evotec Expand LAB150 Bridge Partnership to Include Amgen

TIAP announced today the significant expansion of its flagship LAB150 drug discovery and development program with the addition of Amgen as a strategic and financial partner. Read full press release: https://bwnews.pr/3D3DUXb LAB150 was created in 2017 with Evotec as the first North American BRIDGEs program to accelerate the development of novel therapeutics from our Members. Today’s announcement not only provides pre-seed capital of US$14M to these emerging drug development projects but also significant expertise and mentorship to our local scientists and innovators from ... Read more

TIAP & Amgen Co-funds transformative projects to support new venture development

December 8, 2020 TIAP announces co-funding of transformative projects with Amgen to support new venture development Toronto Innovation Acceleration Partners (TIAP) is excited to announce co-investments made with a key strategic partner, Amgen Inc., into three translational life sciences projects from its members: University of Toronto, University Health Network (UHN) and The Hospital for Sick Children (SickKids). The TIAP-Amgen partnership, formalized in 2019, has an objective to jointly fund nascent technologies managed by TIAP on behalf of its Toronto-based member institutions. The two organizations ... Read more

Zucara Therapeutics Announces US$21M Series A Financing

– Proceeds to Fund Development of ZT-01 Through Phase 2 Clinical Trials – – Series A Financing led by the Perceptive Xontogeny Venture Fund  – TORONTO, March 31, 2020 (GLOBE NEWSWIRE) -- Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has closed a US$21 million Series A Financing led by the Perceptive Xontogeny Venture Fund (“PXV Fund”). The proceeds from the financing will fund Phase 1 and ... Read more

Fibrocor and Galapagos Sign Expanded Collaboration in Fibrosis

Mechelen, Belgium and Toronto, Canada; 15 January 2020, 7.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) and Fibrocor Therapeutics Inc. (Fibrocor) today announced an expanded collaboration focused on novel targets in fibrosis, with Galapagos taking an equity stake in Fibrocor. Fibrocor is a privately held Canadian company specializing in the development of tissue-specific therapeutics to treat fibrotic diseases of the kidney, liver, lung and other organs. To date, the company has successfully identified a suite of novel targets in fibrosis through ... Read more

TIAP Enters Partnership to Establish Venture Capital Fund

TIAP and DAYLI Partners, a leading biotech venture caital firm in South Korea, are collaborating on the creation of a new venture capital fund focused on biotech and health sciences in Canada. The joint investment team will identify & invest in seed stage companies primarily in Ontario with a portion of the fund allocated to Korean companies with high potential to expand to Ontario. Read more here: http://bit.ly/35FH40K   Read more

Amgen Deal in Re$earch Money

In their September 11, 2019 online edition as part of their "Innovation this Week" newsletter, Re$earch Money talked about TIAP's partnership agreement with Amgen: "A few days after celebrating its 10th anniversary and changing its name to Toronto Innovation Acceleration Partners (TIAP), the commercialization organization formerly known as MaRS Innovation announced a new collaboration with the biotechnology company Amgen. The aim of the collaboration is to identify and jointly fund disruptive technologies derived from discovery research conducted in Toronto and managed by ... Read more

BetaKit Article on Amgen Partnership

Jessica Galang of BetaKit, a Canadian online publication on start-up news and tech innovation, writes about TIAP's recently announced strategic partnership with Amgen.  Read more here: http://bit.ly/2lSDVYE   Read more

TIAP Announces Strategic Partnership with Amgen

Toronto, Ontario, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Toronto Innovation Acceleration Partners (TIAP – formerly MaRS Innovation), a leading member-based Canadian provider of venture builder expertise in the early-stage health science field, is pleased to announce the establishment of a collaboration with Amgen, a global leader in the biotechnology industry. Under the terms of the agreement, Amgen and TIAP will jointly fund nascent technologies managed by TIAP on behalf of its Toronto-based member institutions. The two organizations will collaborate in a proactive ... Read more

LAB150 adds project with focus on mental health

Toronto, ON, June 11, 2019 (GLOBE NEWSWIRE) -- It is estimated that 5% of the global population is affected by Major Depressive Disorder (MDD) at any given time. While there are many antidepressant drugs on the market, most of these drugs need weeks to take effect, if at all. This exciting new project hopes to develop a novel rapid-acting antidepressant that has the potential to provide patient relief much faster than conventional treatments. The project builds on years of research led by Dr. ... Read more

Triphase Accelerator Enters Partnership with Celgene for Leukemia Therapy

Toronto, ON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Triphase Accelerator, a Toronto-based drug development company, has entered into a new strategic partnership with Celgene Corporation. The focus of the collaboration will be on a pre-clinical therapeutic developed by the Ontario Institute for Cancer Research (OICR) for the treatment of leukemia and other blood cancers, specifically targeting the WDR5 protein. Under the terms of the agreement, Celgene has the option to acquire TRPH-395 from Triphase Accelerator. Celgene will pay an upfront amount of ... Read more
Page 1 of 512345